Skip to content
Medical Health Aged Care

Cleo Diagnostics Enhances Board Capacity

Cleo Diagnostics Limited ASX.COV 2 mins read

MELBOURNE, AUSTRALIA, 2 October, 2023: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) confirms current Chief Scientific Officer and Executive Director, Dr Andrew Stephens, role will move to full-time effective 1 October, 2023.

Following the Company’s successful listing on the ASX in August, Dr Andrew Stephens has agreed to expand his commitment to the Company by moving his Chief Scientific Officer and Executive Director responsibilities to full-time, up from three days per week part-time. All remaining terms and conditions of Dr Stephens employment agreement are unchanged.

The enhancement to Cleo’s Board capacity is designed to direct clear executive focus on the Company’s phased development strategy to deliver a simple and accurate blood test capable of detecting ovarian cancer at every stage.

Commenting on the enhanced Board capacity, CLEO Chief Executive, Richard Allman, said:
“It is pleasing to see Dr Stephens expand his time commitment to Cleo which will effectively allow the Company to step up our ability to execute on our development program and strategy.  It also further reinforces the confidence and conviction Cleo has in bringing our cancer diagnostics technology to market as soon as possible.”

Dr Andrew Stephens, added:
“The urgency to address the global unmet meet for accurate and early diagnosis of ovarian cancer is clear.  I look forward to dedicating my focus full-time alongside the Board, my colleagues, and partners to advance Cleo’s ambition to address ovarian cancer through a simple and accurate blood test.

 


About us:

About Cleo DIagnostics

CleoDX aims to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease.  The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, Cleo has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests. 

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. Cleo is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.


Contact details:

Elvis Jurcevic
Investor Relations
+61 408 268 271
ej@cleodx.com

More from this category

  • Medical Health Aged Care
  • 26/05/2024
  • 07:25
Royal Australian College of GPs

RACGP ready to take on Far North Queensland GP training

The Royal Australian College of GPs (RACGP) has emphasised its readiness to prepare GPs to serve the north of the state. In February, the College said it was ready to take on GP training in the region after James Cook University announced it would transition away from GP training in 2024. Training will officially change over to the RACGP on 10 June, after extensive preparation and careful management to ensure a seamless transition. The College will continue existing training agreements with registrars, supervisors, and practices for the remainder of 2024. In 2023, the College successfully managed the onboarding of GP…

  • Contains:
  • Medical Health Aged Care
  • 26/05/2024
  • 04:31
Dementia Australia

Join us TODAY for Brisbane Memory Walk & Jog

What: Dementia Australia’sBrisbane Memory Walk & Jog When: Sunday 26 May, from 7.30am Who: More than 1,110 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Special guests Dementia Australia Ambassadors Wally Lewis AM and Takaya Honda. Where: Rocks Riverside Park, Seventeen Mile Rocks For more information visit: www.memorywalk.com.au Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We…

  • Contains:
  • Medical Health Aged Care
  • 26/05/2024
  • 04:30
Dementia Australia

Join us TODAY for Perth Memory Walk & Jog

What: Dementia Australia’sPerth Memory Walk & Jog When: Sunday 26 May, from 7.30am Who: More than 880 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Where: Burswood Park, Burswood. For more information visit: www.memorywalk.com.au Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.